Stereotaxis Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Stereotaxis şirketinin toplam hissedar öz sermayesi $16.2M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $50.9M ve $34.7M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$10.66m
Eşitlik	US$16.22m
Toplam yükümlülükler	US$34.71m
Toplam varlıklar	US$50.94m

Son finansal sağlık güncellemeleri

Is Stereotaxis (NYSEMKT:STXS) A Risky Investment?

Jan 28

Recent updates

US$9.33 - That's What Analysts Think Stereotaxis, Inc. (NYSEMKT:STXS) Is Worth After These Results

Feb 28

Is Stereotaxis (NYSEMKT:STXS) A Risky Investment?

Jan 28

Investors Who Bought Stereotaxis (NYSEMKT:STXS) Shares Five Years Ago Are Now Up 597%

Dec 24

What Kind Of Investors Own Most Of Stereotaxis, Inc. (NYSEMKT:STXS)?

Nov 19

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: STXS 'nin kısa vadeli varlıkları ( $28.8M ) kısa vadeli yükümlülüklerini ( $20.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: STXS şirketinin kısa vadeli varlıkları ( $28.8M ) uzun vadeli yükümlülüklerini ( $14.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: STXS borçsuzdur.

Borcun Azaltılması: STXS un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: STXS şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: STXS un, serbest nakit akışı her yıl % 24.6 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Stereotaxis Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Stereotaxis (NYSEMKT:STXS) A Risky Investment?

Recent updates

Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China

New major risk - Financial position

New minor risk - Share price stability

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Stereotaxis, Inc. to Report Q3, 2024 Results on Nov 11, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Stereotaxis, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Stereotaxis Announces the Appointment of Nachum 'Homi' Shamir to Its Board of Directors

Stereotaxis, Inc. Announces the Successful Treatment of the First Heart Rhythm Patients by Penn Presbyterian Medical Center Utilizing the Advanced Genesis Robotic Magnetic Navigation System

Stereotaxis, Inc. Provides Revenue Guidance for the Full Year 2024

Stereotaxis, Inc. (NYSEAM:STXS) entered into a definitive share purchase agreement to acquire APT EP Inc.

Stereotaxis, Inc. to Report Q1, 2024 Results on May 13, 2024

New minor risk - Shareholder dilution

Stereotaxis, Inc., Annual General Meeting, May 15, 2024

Consensus EPS estimates fall by 20%

Consensus revenue estimates decrease by 10%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Stereotaxis, Inc. Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States

Stereotaxis, Inc. to Report Q4, 2023 Results on Mar 04, 2024

New minor risk - Share price stability

Stereotaxis Announces First Patients Successfully Treated Using Magic Ablation Catheter

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 7.8% to US$4.70

Stereotaxis, Inc. to Report Q3, 2023 Results on Nov 09, 2023

No longer forecast to breakeven

Stereotaxis, Inc. Reiterates Revenue Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Stereotaxis, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Stereotaxis to Initiate First-In-Human Trial to Support CE Mark Application of Magic Catheter

Price target decreased by 7.5% to US$4.90

Stereotaxis, Inc. Announces the First Treatment of Patients with Newly Launched Genesis Robotic Magnetic Navigation System At Advocate Christ Medical Center in Chicago, Illinois

Consensus EPS estimates fall by 21%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2025

Price target decreased by 7.1% to US$5.42

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Stereotaxis, Inc. to Report Q4, 2022 Results on Mar 03, 2023

Stereotaxis Announces the Successful Treatment of Patients Using the Latest Genesis Robotic Magnetic Navigation

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$6.63

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Stereotaxis, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Overland Park Regional Medical Center Extends Leadership in Robotic Treatment of Heart Rhythm Disorders with Plans for Second Stereotaxis System

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Stereotaxis, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Stereotaxis, Inc.(NYSEAM:STXS) dropped from Russell 2000 Dynamic Index

Price target decreased to US$9.42

Stereotaxis, Inc. Reiterates Revenue Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$10.25

Insufficient new directors

Stereotaxis, Inc. to Report Q1, 2022 Results on May 10, 2022

Stereotaxis, Inc., Annual General Meeting, May 19, 2022

Consensus revenue estimates fall by 14%

Stereotaxis, Inc. Provides Revenue Guidance for the Year 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Price target decreased to US$10.25

Stereotaxis, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Price target increased to US$11.25

Forecast to breakeven in 2024

Price target increased to US$11.30

Third quarter 2021 earnings released: US$0.061 loss per share (vs US$0.026 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.02 loss per share (vs US$0.032 loss in 2Q 2020)

Insufficient new directors

Price target increased to US$9.25

Forecast to breakeven in 2024

Stereotaxis, Inc. Provides Revenue Guidance for the Year 2021

Stereotaxis to Establish Global Headquarters in Downtown St. Louis Globe Building

US$9.33 - That's What Analysts Think Stereotaxis, Inc. (NYSEMKT:STXS) Is Worth After These Results

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.095 loss in FY 2019)